This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Legend Biotech (LEGN) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Legend Biotech (LEGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Is QIAGEN N.V. (QGEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (QGEN) Outperforming Other Medical Stocks This Year?
Insulet's Omnipod DASH Shines, New Omnipod Uptake Slows Down
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation of the Omnipod 5 launch in 2021.
Abbott Launches Sports Biosensor in Europe, Boosts CGM Wing
by Zacks Equity Research
Abbott (ABT) makes its first non-exclusive collaboration with Atlanta-based sports technology company, Supersapiens.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with strength in its Life Sciences business.
Medtronic's (MDT) TYRX Envelope Study Results Encouraging
by Zacks Equity Research
Medtronic's (MDT) TYRX Envelope lowers infection risks and is cost-effective.
QIAGEN (QGEN) Completes Buyout of NeuMoDx, Expands Portfolio
by Zacks Equity Research
QIAGEN (QGEN) expands portfolio of automated testing solutions to address laboratory needs in almost any setting for molecular diagnostics via the completed buyout of NeuMoDx.
Illumina-CDGN Partner to Create Coronavirus Tracking System
by Zacks Equity Research
Illumina (ILMN) partners with Australia's CDGN to track the national transmission of the virus causing COVID-19.
Bruker's Buyout of Canopy Biosciences Enhances Portfolio
by Zacks Equity Research
Bruker (BRKR) expands its multi-dimensional immune profiling by adding ChipCytometry tools via the acquisition of Canopy Biosciences.
Intuit, Gildan Activewear, Barrick Gold, QIAGEN and AngloGold Ashanti highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Intuit, Gildan Activewear, Barrick Gold, QIAGEN and AngloGold Ashanti highlighted as Zacks Bull and Bear of the Day
CVS Health Retail Prescription Volume Grows Despite LTC Woes
by Zacks Equity Research
CVS Health's (CVS) consumer centric digital strategy has become even more relevant now.
Cardiovascular Systems Rides on Launches Amid Coronavirus Woes
by Zacks Equity Research
Cardiovascular Systems' (CSII) encouraging REACH PVI study outcome and launch of a physician finder are positives.
Boston Scientific Launches DBS System in Europe Post Approval
by Zacks Equity Research
Boston Scientific (BSX) aims to optimize therapy outcomes via the fourth-generation Vercise Genus DBS System's post-regulatory clearance in Europe.
3 Low-Beta Stocks to Combat Coronavirus-Induced Choppy Market
by Nilanjan Banerjee
To combat market volatility, it is important to create a portfolio of low-beta stocks.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
Medtronic Receives FDA's Go Ahead for EFS Study on TTVR
by Zacks Equity Research
Medtronic (MDT) begins the FDA-approved EFS of Intrepid TTVR system following the receipt of the Breakthrough Device Designation from the regulatory authority.
National Vision Banks on Contact Lens Sales Amid Coronavirus Woes
by Zacks Equity Research
National Vision (EYE) sales bear the impact of unfavorable timing of unearned revenues.
Coronavirus Test Makers With Scope to Maximize Investor Benefits
by Urmimala Biswas
The surge in new coronavirus infections broadens the scope for antigen and antibody tests.
Intersect ENT, AllianceRx Execute Pharmacy-Services Agreement
by Zacks Equity Research
Intersect ENT (XENT) partners with AllianceRx to expand the access to SINUVA Sinus Implant.
Henry Schein Partners MouthWatch to Grow in Teledentistry
by Zacks Equity Research
Henry Schien's (HSIC) customer base is likely to benefit from the Teledent platform.
QIAGEN, Ellume Extend Alliance for COVID-19 Antigen Test
by Zacks Equity Research
QIAGEN (QGEN) extends partnership with Ellume to offer the second COVID-19 test utilizing the latter's technology and strengthening its own COVID-19-testing portfolio.
BeyondSpring (BYSI) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
BeyondSpring (BYSI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Henry Schein (HSIC) Enters Into New Dental Deal With Zyris
by Zacks Equity Research
Henry Schien (HSIC) is set to be the exclusive distributor of Zyris products like Isolite 3, Isovac 2, Isodry and the company's patented single-use Mouthpieces.
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Abbott Begins BTK Clinical Trial to Evaluate DRS Therapy
by Zacks Equity Research
Abbott (ABT) aims to provide a new treatment option for patients with CLI BTK, thus eliminating the need for any additional treatment.